China Pharma Holdings, Inc. — Q3 2016 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2016. The company manufactures and sells generic and branded pharmaceuticals and biochemical products in China through its subsidiary. Financial statements are unaudited and presented in U.S. dollars.
Financial results and position
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | $3.13 million | $4.48 million | $10.31 million | $15.85 million |
| Gross profit | $0.35 million | $0.32 million | $1.47 million | $1.33 million |
| Gross margin | 11.2% | 7.2% | About 14% | About 8% |
| Operating income (loss) | $(1.55) million | $3.19 million | $(5.09) million | $(8.28) million |
| Net income (loss) | $(1.75) million | $2.93 million | $(5.76) million | $(9.16) million |
| Operating cash flow | Not presented quarterly | Not presented quarterly | $1.42 million | $0.65 million |
Q3 diluted loss per share was $0.04, versus earnings per share of $0.07 a year earlier. Nine-month loss per share was $0.13, compared with $0.21 in 2015. Nine-month cash used in investing was $86,350 and cash used in financing was $3.80 million; cash and equivalents fell by $2.60 million to $3.65 million. The balance sheet also showed $1.47 million of restricted cash and $21,546 of banker’s acceptances.
At September 30, total current assets were $20.99 million and current liabilities were $12.95 million. Total liabilities were $22.47 million. Debt included $10.50 million outstanding under the construction facility ($1.50 million current) and $2.25 million of short-term notes payable. The company reported $1.47 million of banker’s acceptance notes payable, matched by restricted cash. It had no remaining availability under the disclosed credit facilities.
Material changes and notable items
- Nine-month revenue declined 35%; Q3 revenue declined 30%. Management attributed weakness to lost market share following missed provincial tenders related to delayed GMP certification, healthcare price controls, and 2016 CFDA enforcement activity that disrupted distributors’ purchasing and promotion.
- Anti-viral/infection and respiratory products drove the largest sales decline: down 36% for the nine-month period. Q3 cost of revenue was 86.3% of sales; management said product mix contributed to margin pressure. Lower inventory-obsolescence charges helped reported year-to-date gross margin.
- Nine-month operating and net losses improved from 2015, primarily because bad-debt expense and inventory obsolescence were lower. Q3 results worsened from the prior-year quarter, reflecting lower sales, sharply lower subsidy income, and impairment expense. Q3 2015 included a $3.16 million bad-debt benefit, making the comparison particularly uneven.
- The company recorded $1.47 million of impairment on advances for medical-formula purchases after identifying three impaired advances; $644,696 of that charge was recorded in Q3. It remained obligated to pay laboratories about $4.4 million over roughly four years as contract milestones are completed.
- Receivables remain a major credit-quality concern: net trade receivables were $4.01 million after a $29.38 million allowance. The filing says about $30 million of receivables related to sales more than one year old and that management believes most are collectible. At September 30, 78.9% of receivables were over 720 days old; three customers represented 50.6% of receivables.
Outlook, risks and liquidity
Management said it expected operating cash generation to cover working capital and anticipated capital expenditures for the next 12 months, while cautioning that weaker-than-planned operations could require additional financing or spending reductions. The company was seeking renewal of its short-term credit line, with no assurance of renewal on acceptable terms. Management acknowledged there had been no immediate reversal in sales trends, but said it believed the operating and financial position provided a foundation for steadier growth. No numerical revenue or earnings guidance was provided.
Management said it would not seek renewal of its National High-Tech Enterprise status; the disclosed preferential PRC tax rate was 15% through 2016 and 25% thereafter. Product approvals face longer timelines and higher costs due to tighter CFDA review requirements and generic-drug consistency evaluations. Other disclosed risks include distributor and tender disruption, aged receivables, dependence on suppliers (one supplier accounted for 21.7% of nine-month raw-material purchases), PRC currency-conversion and remittance controls, and exposure to PRC political, regulatory and economic conditions. Management reported effective disclosure controls and no material changes in internal control over financial reporting.
Important facts for investors to verify
- Whether the short-term credit line was renewed and confirm the timing of repayment: the filing’s liquidity discussion says both installments were paid, while Note 7 says the second installment was paid after quarter-end.
- Collection experience for the heavily aged receivables, adequacy of the $29.38 million allowance, and the basis for management’s collectability assessment.
- Progress on restoring tender access and sales following GMP certification and distributor inspections, including performance of the largest product categories.
- Recoverability of remaining formula advances, status of CFDA approvals, and potential effects of the approximately $4.4 million milestone commitment.
- Availability of cash for parent-company needs: management stated the $3.65 million cash balance was considered indefinitely reinvested in the PRC subsidiary; PRC controls may restrict remittances.